WFRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient entry. WFRD is in a strong uptrend, but it’s extended (RSI 73) and sitting just below near-term resistance (94.70). With no Intellectia buy signals today and latest quarter showing meaningful YoY declines in revenue/EPS, the risk-reward for buying immediately at ~$94 is not attractive. I’d rate it a HOLD at current levels rather than an outright buy.
Trend is bullish: moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), and MACD histogram is above zero and expanding (0.443), supporting ongoing upside momentum. However, RSI_6 at ~72.95 signals the stock is stretched/near overbought, which often precedes short pullbacks or consolidation. Price is also near resistance R1 ~94.70 (current ~94), so upside from here is less favorable unless it cleanly breaks above R1; key downside reference is the pivot/support zone near 89.38 (with deeper supports ~84.06 and ~80.77).
Intellectia Proprietary Trading Signals
Hedge funds are accumulating (reported buying amount up ~427% QoQ), which supports institutional sentiment. Wall Street tone is broadly constructive with multiple Overweight/Buy ratings and raised targets into late 2025/early 2026, reflecting expectations that the oilfield services downcycle is bottoming and that Saudi/Mexico activity could improve. Options flow is call-heavy (volume put/call 0.22), consistent with bullish near-term sentiment.
and pressing into resistance (~94.70), increasing the odds of a near-term pullback/consolidation rather than immediate clean upside. No news/catalysts in the last week to drive an event-based breakout. No notable insider buying trend recently (insiders neutral). No recent congress trading data available, so there’s no supportive signal from that channel.
2025/Q3 results showed contraction: revenue $1.232B (-12.56% YoY), net income $81M (-48.41% YoY), EPS $1.12 (-46.41% YoY), and gross margin 31.49% (-9.82% YoY). The growth trend in the latest quarter is negative and suggests the business is still working through a softer part of the cycle.
Recent analyst trend: targets were raised meaningfully in Dec 2025 (Barclays to $111 from $81; Citi to $93 from $77; Piper to $95 from $80), reflecting improved 2026 outlook framing. In Jan 2026, Barclays trimmed slightly to $109 from $111 but maintained Overweight—more of a fine-tune than a thesis change. Overall Wall Street pros: improving cycle narrative into 2026, potential Mexico turning tailwind, multiple Overweight/Buy stances with targets above current price (notably Barclays ~$109). Cons: at least one Neutral initiation (UBS $82) arguing much optimism is already priced after a large rally, and the company’s latest YoY financial declines back up the caution.
